Logo image of SLGL

SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Fundamental Analysis

NASDAQ:SLGL - Nasdaq - IL0011417206 - Common Stock - Currency: USD

15.44  +0.19 (+1.25%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SLGL. SLGL was compared to 193 industry peers in the Pharmaceuticals industry. SLGL has a great financial health rating, but its profitability evaluates not so good. SLGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLGL has reported negative net income.
In the past year SLGL has reported a negative cash flow from operations.
SLGL had negative earnings in 4 of the past 5 years.
SLGL had a negative operating cash flow in each of the past 5 years.
SLGL Yearly Net Income VS EBIT VS OCF VS FCFSLGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

SLGL has a Return On Assets (-29.52%) which is in line with its industry peers.
SLGL has a Return On Equity (-36.67%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.52%
ROE -36.67%
ROIC N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
SLGL Yearly ROA, ROE, ROICSLGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLGL Yearly Profit, Operating, Gross MarginsSLGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLGL has about the same amount of shares outstanding.
SLGL has more shares outstanding than it did 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLGL Yearly Shares OutstandingSLGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SLGL Yearly Total Debt VS Total AssetsSLGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -5.24, we must say that SLGL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SLGL (-5.24) is worse than 60.10% of its industry peers.
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.24
ROIC/WACCN/A
WACC9.07%
SLGL Yearly LT Debt VS Equity VS FCFSLGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.92 indicates that SLGL has no problem at all paying its short term obligations.
SLGL has a Current ratio of 5.92. This is in the better half of the industry: SLGL outperforms 76.17% of its industry peers.
A Quick Ratio of 5.92 indicates that SLGL has no problem at all paying its short term obligations.
SLGL's Quick ratio of 5.92 is fine compared to the rest of the industry. SLGL outperforms 76.17% of its industry peers.
Industry RankSector Rank
Current Ratio 5.92
Quick Ratio 5.92
SLGL Yearly Current Assets VS Current LiabilitesSLGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.90% over the past year.
Looking at the last year, SLGL shows a very strong growth in Revenue. The Revenue has grown by 605.30%.
The Revenue for SLGL have been decreasing by -12.81% on average. This is quite bad
EPS 1Y (TTM)42.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.29%
Revenue 1Y (TTM)605.3%
Revenue growth 3Y-28.28%
Revenue growth 5Y-12.81%
Sales Q2Q%121.24%

3.2 Future

The Earnings Per Share is expected to grow by 35.73% on average over the next years. This is a very strong growth
SLGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.05% yearly.
EPS Next Y-42.86%
EPS Next 2Y0%
EPS Next 3Y1.18%
EPS Next 5Y35.73%
Revenue Next Year-42.11%
Revenue Next 2Y-12.86%
Revenue Next 3Y8.74%
Revenue Next 5Y37.05%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SLGL Yearly Revenue VS EstimatesSLGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SLGL Yearly EPS VS EstimatesSLGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGL Price Earnings VS Forward Price EarningsSLGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGL Per share dataSLGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y1.18%

More info and screens

0

5. Dividend

5.1 Amount

SLGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (8/15/2025, 8:00:02 PM)

15.44

+0.19 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-13 2025-11-13
Inst Owners27.81%
Inst Owner Change-92.9%
Ins Owners5.14%
Ins Owner ChangeN/A
Market Cap43.08M
Analysts82.86
Price TargetN/A
Short Float %2.1%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.57%
Min Revenue beat(2)-86.37%
Max Revenue beat(2)95.51%
Revenue beat(4)2
Avg Revenue beat(4)87.42%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)405.4%
Revenue beat(8)4
Avg Revenue beat(8)42.2%
Revenue beat(12)4
Avg Revenue beat(12)2.1%
Revenue beat(16)6
Avg Revenue beat(16)-4.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-4.68
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-4.98
FCFYN/A
OCF(TTM)-4.98
OCFYN/A
SpS4.14
BVpS10.34
TBVpS10.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.52%
ROE -36.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.86%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.92
Quick Ratio 5.92
Altman-Z -5.24
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)23.47%
Cap/Depr(5y)26.73%
Cap/Sales(3y)4.34%
Cap/Sales(5y)3.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.29%
EPS Next Y-42.86%
EPS Next 2Y0%
EPS Next 3Y1.18%
EPS Next 5Y35.73%
Revenue 1Y (TTM)605.3%
Revenue growth 3Y-28.28%
Revenue growth 5Y-12.81%
Sales Q2Q%121.24%
Revenue Next Year-42.11%
Revenue Next 2Y-12.86%
Revenue Next 3Y8.74%
Revenue Next 5Y37.05%
EBIT growth 1Y59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.66%
OCF growth 3YN/A
OCF growth 5YN/A